Trial Profile
Post-Marketing Surveillance of Kadcyla in Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 06 Dec 2021 Status changed from active, no longer recruiting to completed.
- 22 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2021 Planned number of patients changed from 3000 to 500.